Pinebridge Investments L.P. Has $407,000 Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Pinebridge Investments L.P. lowered its position in Illumina, Inc. (NASDAQ:ILMNGet Rating) by 56.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,071 shares of the life sciences company’s stock after selling 1,390 shares during the quarter. Pinebridge Investments L.P.’s holdings in Illumina were worth $407,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ILMN. Patten Group Inc. lifted its holdings in shares of Illumina by 0.9% in the fourth quarter. Patten Group Inc. now owns 3,082 shares of the life sciences company’s stock valued at $1,173,000 after purchasing an additional 29 shares in the last quarter. EFG Asset Management Americas Corp. raised its holdings in Illumina by 2.2% during the fourth quarter. EFG Asset Management Americas Corp. now owns 1,372 shares of the life sciences company’s stock worth $522,000 after acquiring an additional 29 shares in the last quarter. MML Investors Services LLC raised its holdings in Illumina by 0.8% during the third quarter. MML Investors Services LLC now owns 3,898 shares of the life sciences company’s stock worth $1,581,000 after acquiring an additional 30 shares in the last quarter. Corient Capital Partners LLC raised its holdings in Illumina by 1.7% during the third quarter. Corient Capital Partners LLC now owns 1,808 shares of the life sciences company’s stock worth $733,000 after acquiring an additional 30 shares in the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co increased its position in Illumina by 3.1% during the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 990 shares of the life sciences company’s stock worth $377,000 after buying an additional 30 shares during the last quarter. Institutional investors own 86.62% of the company’s stock.

NASDAQ ILMN opened at $243.22 on Wednesday. The business has a fifty day moving average price of $316.96 and a two-hundred day moving average price of $348.62. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.85 and a quick ratio of 1.54. Illumina, Inc. has a fifty-two week low of $208.35 and a fifty-two week high of $526.00. The stock has a market capitalization of $38.21 billion, a PE ratio of 52.87, a PEG ratio of 1.82 and a beta of 0.99.

Illumina (NASDAQ:ILMNGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The life sciences company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.20. Illumina had a return on equity of 8.37% and a net margin of 15.04%. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same period in the prior year, the company earned $1.89 EPS. Illumina’s revenue was up 11.9% compared to the same quarter last year. As a group, sell-side analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

In related news, SVP Charles Dadswell sold 368 shares of the firm’s stock in a transaction on Monday, March 28th. The stock was sold at an average price of $342.83, for a total transaction of $126,161.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Aimee L. Hoyt sold 2,474 shares of the firm’s stock in a transaction on Tuesday, April 12th. The stock was sold at an average price of $350.51, for a total value of $867,161.74. Following the transaction, the senior vice president now directly owns 5,342 shares of the company’s stock, valued at $1,872,424.42. The disclosure for this sale can be found here. Insiders sold a total of 5,198 shares of company stock valued at $1,819,471 over the last quarter. 0.13% of the stock is owned by corporate insiders.

ILMN has been the topic of a number of recent analyst reports. Robert W. Baird lowered their price target on Illumina from $437.00 to $380.00 in a research report on Friday, February 11th. Cowen lowered their price target on Illumina from $506.00 to $492.00 in a research report on Friday, May 6th. OTR Global raised Illumina from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 29th. Cowen decreased their target price on Illumina from $506.00 to $492.00 in a research report on Friday, May 6th. Finally, Canaccord Genuity Group decreased their target price on Illumina from $555.00 to $520.00 and set a “buy” rating on the stock in a research report on Friday, May 6th. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average price target of $433.08.

Illumina Profile (Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Further Reading

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.